CClinicalTrials.gg
Sign In
Not yet recruitingNCT06746571Updated Dec 24, 2024

Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients

An interventional study of complete blood count in Lymphoblastic Leukemia, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 5 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jan 2026, 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
5 Years to 50 Years
Sex
All
01

Study summary

Role of cbc indices in acute lymphoblastic leukemia patients to explore the prognostic role of them in prediction the response to induction chemotherapy

Read the detailed description

Role of neutrophil to lymph ratio , lymphocyte to monocyte ratio and platelet to lymphocyte in acute lymphoblastic leukemia adults and pediatric patients to explore the prognostic role of them in prediction the response to induction chemotherapy

02

Conditions studied

  • Lymphoblastic Leukemia
03

In context

Leukemia

5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.

This study's planned enrollment of 100 is above the median of 38 across 4,247 interventional studies indexed under Leukemia.

Browse Leukemia studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients newly diagnosed ALL

Exclusion criteria

Exclusion Criteria:

  • others malignanices
  • ALL on therapy
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Interventions

  • Diagnostic testcomplete blood count

    measure cbc and blood ratios to compare their values with respone of patients to treatment

06

What researchers measure

Primary outcomes

  1. neutrophil to lymphocyte ratio

    count of neutophils comparing lymphocytees

    Time frame: 1 year

07

Study locations

1 site
  • Sohag university Hospital
    Sohag, Sohag, Egypt
    • Magdy M Amin, professor · Contact
08

References and documents

Publications

  • Jiang Z, Dong Z, Wang L, Jiang W. Method for Diagnosis of Acute Lymphoblastic Leukemia Based on ViT-CNN Ensemble Model. Comput Intell Neurosci. 2021 Aug 21;2021:7529893. doi: 10.1155/2021/7529893. eCollection 2021. PubMed 34471407 ↗
  • Gavralidis A, Brunner AM. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2020 Aug;15(4):294-304. doi: 10.1007/s11899-020-00591-4. PubMed 32445026 ↗
  • Haider RZ, Ujjan IU, Khan NA, Urrechaga E, Shamsi TS. Beyond the In-Practice CBC: The Research CBC Parameters-Driven Machine Learning Predictive Modeling for Early Differentiation among Leukemias. Diagnostics (Basel). 2022 Jan 7;12(1):138. doi: 10.3390/diagnostics12010138. PubMed 35054304 ↗
  • Stefaniuk P, Szymczyk A, Podhorecka M. The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies - A Narrative Review. Cancer Manag Res. 2020 Apr 29;12:2961-2977. doi: 10.2147/CMAR.S245928. eCollection 2020. PubMed 32425606 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06746571
Lead sponsor
Sohag University
Responsible party
Omnia Aly Mohamed (resident-clinical pathology sohag university hospital, Sohag University) — Principal investigator
First posted
Dec 24, 2024
Start date
Jan 15, 2025 (estimated)
Primary completion
Jan 15, 2026 (estimated)
Completion
Jan 15, 2026 (estimated)
Last update
Dec 24, 2024

Study contacts

omnia A Mohammed, resident
Contact
omnia_ali_post@med.sohag.edu.eg
01121809920
heba a Ahmed, assistant professor
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Leukemia→

Other studies from this sponsor

Sohag University

Start the discussion